Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CatalYm
CatalYm is a preclinical biotech company developing therapies to address cancer resistance.
Biotech
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Amylyx preps for GLP-1 launch with new CCO. Andy Orth given key to the City. Antag taps Bayer vet as CEO.
Darren Incorvaia
,
Zoey Becker
Jan 10, 2025 8:30am
CatalYm cashes in on early-stage cancer data with $150M series D
Jul 16, 2024 5:00am
